Special Issue

PANoptosis in Viral Infection

Message from the Guest Editor

Innate immunity provides a critical first line of defence against infections, including viruses. The sensing of viruses by cytosolic innate immune sensors activates signalling pathways that can drive inflammatory cell death, as well as the production of antiviral interferons and proinflammatory cytokines. While inflammatory cell death can be beneficial to clear viral infections, it can also lead to excess inflammation and pathophysiology; therefore, the tight regulation of cell death in response to viral infections is critical. This Special Issue on PANoptosis in viral infection focuses on viral sensing and the activation of PANoptosis, a unique, lytic, innate immune, and inflammatory cell death pathway that is driven by caspases as well as RIPKs and regulated by PANoptosome complexes. Multiple PANoptosomes have been identified in response to viral infection, including ZBP1- and AIM2-PANoptosomes. This collection of articles will discuss the cellular and molecular mechanisms of PANoptosis and PANoptosomes, providing new insights into therapeutic targets for antiviral therapies and strategies with which to mitigate immunopathogenesis.

Guest Editor

Dr. Thirumala-Devi Kanneganti

Center of Excellence for Innate Immunity and Inflammation, Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA

Deadline for manuscript submissions

28 February 2026



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/192500

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAq, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).